Blood test may let lung transplant patients ditch antiviral drugs sooner
NCT ID NCT05708755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a blood test that measures immune protection against a common virus (CMV) can safely shorten the time lung transplant recipients need to take antiviral medication. About 50 participants will have their antiviral treatment duration guided by the test results. The goal is to reduce drug side effects while still preventing viral infections after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT; COMPLICATIONS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- New drug may protect kidneys in lung transplant patients
- Massive lung transplant study seeks 2,600 patients to unlock better care
- Lung transplant patients may skip some clinic visits with new app
- Light sensor may predict kidney failure after lung transplant
- Inhaled cyclosporine aims to halt lung transplant rejection